After selling its hemophilia drug program to an Illinois company earlier this year, Ipsen has announced it will relocate its U.S. research and development activities to Cambridge in 2014. … The Massachusetts Life Sciences Center, which previously administered a research matching grant to Ipsen, announced the move.
